https://sputnikglobe.com/20210820/worlds-first-dna-based-anti-covid-vaccine-gets-emergency-administration-approval-in-india-1083671706.html
World's First DNA-based Anti-COVID Vaccine Gets Emergency Administration Approval in India
World's First DNA-based Anti-COVID Vaccine Gets Emergency Administration Approval in India
Sputnik International
The jab's needle-free injector is suitable for vaccinating kids as they are often scared of needles. 20.08.2021, Sputnik International
2021-08-20T15:37+0000
2021-08-20T15:37+0000
2022-07-19T10:38+0000
newsfeed
world
covid-19
coronavirus
sars coronavirus
vaccines
https://cdn1.img.sputnikglobe.com/img/07e5/06/16/1083208395_0:223:2851:1826_1920x0_80_0_0_c76c0ca9ed68debc13dfe7d4a09bbbf2.jpg
On Friday, Zydus Cadila's vaccine – ZyCoV-D – received approval for emergency use authorisation (EUA) from the Drug Controller General of India (DCGI). ZyCoV-D is the first COVID-19 vaccine for children in India to be green-lighted, it's also the world's first DNA-based vaccine and will be given to people who are 12 or older.The jab produces the spike protein of the SARS-CoV-2 to elicit an immune response. India's Ministry of Science and Technology said that the interim results from phase three clinical trials in over 28,000 volunteers showed a primary efficacy of 66.6 percent for symptomatic RT-PCR positive cases. It's is largest vaccine trial so far in India for COVID.The ZyCoV-D vaccine has been tested on 1,000 children above the age of 12 – it's an intradermal jab that has to be applied using a "needle-free injector," which helps reduce side effects, the manufacturer says.
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
2021
Sushmita Panda
https://cdn1.img.sputnikglobe.com/img/07e5/05/12/1082926186_0:0:2048:2048_100x100_80_0_0_4474d0d7e27a36878eb8727832be74b4.jpg
Sushmita Panda
https://cdn1.img.sputnikglobe.com/img/07e5/05/12/1082926186_0:0:2048:2048_100x100_80_0_0_4474d0d7e27a36878eb8727832be74b4.jpg
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
https://cdn1.img.sputnikglobe.com/img/07e5/06/16/1083208395_59:0:2790:2048_1920x0_80_0_0_445ca129d3d6929bd87b00e54689bebf.jpgSputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
Sushmita Panda
https://cdn1.img.sputnikglobe.com/img/07e5/05/12/1082926186_0:0:2048:2048_100x100_80_0_0_4474d0d7e27a36878eb8727832be74b4.jpg
newsfeed, covid-19, coronavirus, sars coronavirus, vaccines
newsfeed, covid-19, coronavirus, sars coronavirus, vaccines
World's First DNA-based Anti-COVID Vaccine Gets Emergency Administration Approval in India
15:37 GMT 20.08.2021 (Updated: 10:38 GMT 19.07.2022) The jab's needle-free injector is suitable for vaccinating kids as they are often scared of needles.
On Friday, Zydus Cadila's
vaccine – ZyCoV-D – received approval for emergency use authorisation (EUA) from the Drug Controller General of India (DCGI). ZyCoV-D is the first COVID-19 vaccine for children in India to be green-lighted, it's also the world's first DNA-based vaccine and will be given to people who are 12 or older.
The jab produces the spike protein of the SARS-CoV-2 to elicit an immune response.
India's Ministry of Science and Technology said that the interim results from phase three
clinical trials in over 28,000 volunteers showed a primary efficacy of 66.6 percent for symptomatic RT-PCR positive cases. It's is largest vaccine trial so far in India for COVID.
"This vaccine had already exhibited robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials carried out earlier. Both the Phase I/II and Phase III clinical trials have been monitored by an independent Data Safety Monitoring Board (DSMB)," India's government said in a statement.
The ZyCoV-D vaccine has been tested on 1,000 children above the age of 12 – it's an intradermal jab that has to be applied using a "needle-free injector," which helps reduce side effects, the manufacturer says.